Overview
Oral Challenge in the Pediatric ED
Status:
Active, not recruiting
Active, not recruiting
Trial end date:
2021-12-04
2021-12-04
Target enrollment:
0
0
Participant gender:
All
All
Summary
Our primary objective is to demonstrate the feasibility of utilizing a novel penicillin allergy questionnaire in the PED to identify a low-risk group of patients who will complete an oral challenge in the PED to test for an IgE-mediated allergic reaction. This project began as a single site feasibility study, however it has now transitioned to include 2 other collaborative sites for enrollment. We have entered into a single IRB with 1 of the collaborative sites. The other site has elected to do their own IRB. Our secondary objective is to examine whether health care outcomes and prescription-related costs are comparable between children who are de-labeled as penicillin allergic after an oral challenge compared to a standard of care group who are not challenged in the PED.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Medical College of WisconsinTreatments:
Amoxicillin
Penicillins
Criteria
Inclusion Criteria:- Children aged 2-16 with a parent/guardian (hereafter termed parent) reported history
of allergy to a penicillin antibiotic in which the reported allergic reaction occurred
at least six months prior to the current PED visit.
- Only children well enough to be discharged to home at the conclusion of the PED visit
are eligible.
Exclusion Criteria:
- Children will be excluded if they have a history of developmental delay or inability
to communicate the effects of an allergic reaction (non-verbal).
- Any contraindication to allergy testing will also result in exclusion
- (i.e. history of a severe allergic reaction to skin tests,,
- anaphylaxis in the past six weeks,
- known pregnancy
- child has a history of a condition that requires a beta blocker medicine for cardiac
conditions, high blood pressure, migraine headaches, or eye drops for glaucoma (e.g.
propranolol, metoprolol, atenolol and Timoptic®, or Betoptic® eye drops).
- Children who present to the PED with a rash, vomiting or current asthma symptoms
including coughing, wheezing or breathing problems will also be excluded to ensure
these do not mask reactions to an oral challenge.
- Patients deemed too acutely ill for participation (triage level 1 or 2 or as
determined by the ED patient care team) will be excluded from the study.
- During this pilot study, we will exclude non-English speaking families. However, in
subsequent studies we will include the non-English speaking population.
- Children who are wards of the state, in foster care or police custody or detention
will be excluded.
- Children with any basal condition (trauma, infection, minor accidents, etc..) will be
able to participate in the study provided they and their family are willing and do not
meet the above-mentioned exclusion criteria.